Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin glargine U300 versus Lantus in children and adolescents with type 1 diabetes
2015-002084-42Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diabetes mellitus type 1 (T1D) comparing HOE901-U300 with Lantus (2 arms). Primary endpoint: Change from baseline in HbA1c. Started Dec 2015; status: completed.
02
Drugs
insulin glargineinsulin glargine U300
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2015-002084-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002084-42.